Tue, Apr 29, 9:07 PM (23 days ago)
**BridgeBio Pharma, Inc. (BBIO) Q1 2025 Financial Summary** **Financial Health:** - **Revenue:** $116.6 million, down 54.6% YoY due to a decrease in license and services revenue, partially offset by $36.7 million in net product revenue from Attruby sales. - **Net Loss:** $169.6 million, up 373.7% YoY due to increased operating expenses and interest expenses. - **Cash Position:** $540.6 million, down 20.6% from Q4 2024 due to operating cash outflows and debt repayments. **Performance Metrics:** - **Gross Margin:** Not explicitly stated, but cost of revenues was $2.6 million. - **Operating Margin:** -114.4%, reflecting high operating expenses. - **Net Margin:** -145.4%, indicating significant net losses. **Earnings Changes:** - **EPS:** -$0.88, down from -$0.20 in Q1 2024. - **Weighted-Average Shares:** 190.1 million, up from 178.7 million in Q1 2024. **Quarterly Performance:** - **Revenue Trends:** Decline in license and services revenue, offset by product sales. - **Expense Trends:** Increase in R&D, SG&A, and interest expenses. - **Cash Flow:** Negative operating cash flow due to high expenses and investments. **Trends & Uncertainties:** - **Positive Trends:** FDA approvals of Attruby and Beyonttra, product sales initiation. - **Uncertainties:** Regulatory risks, market competition, and operational challenges. **Future Operations Impact:** - **Commercialization:** Focus on Attruby sales and market expansion. - **R&D:** Continued investment in late-stage programs and pipeline development. - **Financing:** Potential need for additional capital to support growth and operations. **Ticker:** BBIO **Note:** Amounts are in thousands, except per share data.